results of internalisation, haemolytic, cytotoxic and antibacterial activity assays, a classification of cationic peptides is advocated. We found eight promising carrier peptides with good penetration ability of which Penetratin, Tat, Buforin and Dhvar4 peptides showed low adverse haemolytic effect. Penetratin, Transportan, Dhvar4 and the hybrid CM15 peptide had the most potent antibacterial activity on Streptococcus pneumoniae (MIC lower than 1.2 μM) and Transportan was effective against Mycobacterium tuberculosis as well. The most selective peptide was the Penetratin, where the effective antimicrobial concentration on pneumococcus was more than 250 times lower than the HC 50 value. Therefore, these peptides and their analogues will be further investigated as drug delivery systems for antimicrobial agents.
Introduction
In the design and development of new antimicrobial drug candidates, delivery to target site is one of the major considerations. However, several libraries of synthetic compounds providing activity against a broad spectrum of pathogens have been discovered so far; the general inability to penetrate the target cells seems to be the main obstacle, especially in the case of diseases that are caused by intracellular bacteria (Brown and Wright 2016) .
The cellular uptake rate and the bioavailability of drug compounds can be enhanced by covalent attachment to appropriate targeting or carrier peptides. Cationic oligopeptides, including cell penetrating peptides (CPP) and Abstract Cationic peptides proved fundamental importance as pharmaceutical agents and/or drug carrier moieties functioning in cellular processes. The comparison of the in vitro activity of these peptides is an experimental challenge and a combination of different methods, such as cytotoxicity, internalisation rate, haemolytic and antibacterial effect, is necessary. At the same time, several issues need to be addressed as the assay conditions have a great influence on the measured biological effects and the experimental setup needs to be optimised. Therefore, critical comparison of results from different assays using representative examples of cell penetrating and antimicrobial peptides was performed and optimal test conditions were suggested. Our main goal was to identify carrier peptides for drug delivery systems of antimicrobial drug candidates. Based on the 1 3 certain antimicrobial peptides (AMP), have the ability to cross the lipid membrane and to access intracellular targets. Several cationic oligopeptides entered clinical trials (Marr et al. 2006; Yeung et al. 2011) . However, lack of cell specificity and extensive cytotoxicity of CPPs still need to be addressed. To improve the therapeutic effect of these peptides, intracellular trafficking and antimicrobial activity with low cytotoxicity toward human host cells are needed. For the calculation of the in vitro selectivity, the haemolytic activity toward human red blood cells (RBC) is often used for the comparison to the antimicrobial activity (Chen et al. 2005) .
Experimental conditions of in vitro assays
To determine the in vitro selectivity of membrane-active cationic peptides, many types of biological assays are described in the literature. Previous studies have warned that the absence of haemolysis or high HC 50 values in certain media (i.e. PBS) can give false results, when the selectivity index is calculated (Saberwal and Nagaraj 1994) . Even in the case of the bee venom Melittin, haemolytic activity can be inhibited if the phosphate concentration is raised (Helmerhorst et al. 1999; Portlock et al. 1990 ). In general, the membrane activity of many cationic peptides is strongly dependent on the ionic strength and salt content of the used media (Helmerhorst et al. 1999; Herbel and Wink 2016) . Raghuraman and colleagues studied the effect of ionic strength on the dynamics and aggregation behaviour of Melittin and they showed that the peptide undergoes a structural transition from a random coil monomer to an α-helical tetramer at high ionic strength .
The most significant differences in the test conditions can be found in the haemolytic assays of peptides. Important variants are as follows: (1) concentration of RBC [0.5% v/v (Hollmann et al. 2016) , 1% (Kobayashi et al. 2000) , 2% (Yang et al. 2013) , 4% (Lee and Lee 2008; Song et al. 2005) , 20% (Chongsiriwatana et al. 2008) , 2 × 10 6 cells/mL (Li et al. 2005) or 2.5 × 10 8 cells/mL (Dathe et al. 1996 (Dathe et al. , 2001 ), 1.2 × 10 9 cells/mL (Zeitler et al. 2013) etc.]; (2) incubation media [PBS (Chongsiriwatana et al. 2008; Dennison and Phoenix 2014; Hollmann et al. 2016; Lee and Lee 2008; Song et al. 2005) , Tris (Dathe et al. 1996 (Dathe et al. , 2001 Zeitler et al. 2013 ), RPMI-1640 or HEPES buffer (Li et al. 2005) , 0.9% NaCl or normal saline (Wu et al. 2014), etc.] ; (3) incubation time [30 min (Hollmann et al. 2016; Wu et al. 2014 ), 1 h (Chongsiriwatana et al. 2008; Dennison and Phoenix 2014; Yang et al. 2013 ), 4 h (Li et al. 2005) or 18-24 h (Mojsoska et al. 2015) ]; (4) used positive control [0.1% Triton-X (Dennison and Phoenix 2014; Lee and Lee 2008; Song et al. 2005) , 1% Triton-X (Mojsoska et al. 2015) , 10% Triton-X (Wu et al. 2014) , distilled water (Hollmann et al. 2016; Yang et al. 2013 ), 2% SDS (Zeitler et al. 2013) , 0.05% saponin (Davanco et al. 2014) ]. There are differences even in the used wavelength at which the optical density of released haemoglobin is determined [λ = 350 nm (Chongsiriwatana et al. 2008) , 405-415 nm (Kaushik et al. 2012; Lee and Lee 2008; Song et al. 2005; Zeitler et al. 2013 ), 540-550 nm (Davanco et al. 2014 Hollmann et al. 2016; Mojsoska et al. 2015; Yang et al. 2013) or 570 nm (Dennison and Phoenix 2014; Wu et al. 2014)] .
Because of the different test conditions, it is questionable whether the results of the haemolytic assays can be properly compared to the antimicrobial activity and/ or cytotoxicity that are usually performed in lower ionic strength media or broths (RPMI, HEPES, DMEM, Bouillon, etc.) . Therefore, we have investigated in the comparative analysis of haemolytic activity, cytotoxicity, cellular uptake and antimicrobial activity of cationic oligopeptides with the aim to clarify the role of experimental conditions such as the cell type, concentration of cells, used media, incubation time, anticoagulant and counter-ion, etc.
Peptide selection
In this project, well-studied cationic oligopeptides which can be considered as representative CPPs and AMPs were chosen for critical analysis. Our goal was to identify peptides as promising antibacterial drug carriers with potent penetrating ability, antibacterial effect and suitable selectivity. Criteria of the peptide selection were the following: size (smaller than 25 amino acids); cationic character; synthetic considerations, such as bearing suitable conjugation site; literature data on membrane activity (e.g., cell penetration and/or antibacterial effect).
In many cases, however, the exact mechanism of bacterial killing of AMPs is not known; these evolutionarily conserved peptides can permeabilise the phospholipid membrane and provoke a broad spectrum of antimicrobial activity against bacteria, viruses, and fungi (Reddy et al. 2004; Yeaman and Yount 2003) . Many antimicrobial peptides were isolated from amphibians, such as Magainin (Zasloff 1987) and Buforin (Park et al. 1996) . Granulysin, a 9 kDa protein found in granules of cytotoxic T lymphocytes and natural killer cells, lyses a variety of tumour and bacterial cells in vitro, and directly kills Mycobacterium tuberculosis (Stenger et al. 1998 ). GranF2, a 23-mer peptide synthetic derivative, represents a helix-loop-helix region, which is postulated to be the membrane-docking part of Granulysin (Andreu et al. 1999) . Histatins are salivary histidine-rich cationic peptides found in human parotid secretion. Synthetic derivatives, including Dhvar4, were studied on the ability to adopt helical conformation which is considered to be the key feature to act as membrane-active antimicrobial peptides (Helmerhorst et al. 1 3 1997). Crot(1-9,38-42) peptide is representing the N-and C-terminus of Crotamine, a toxin found in the venom of rattlesnake (Andreu et al. 1992) . Recently, chimera peptides were developed to improve the biological activity: CM15 is a linear, hybrid AMP composed of Cecropin A (1-7) and Melittin (2-9) (Radis-Baptista et al. 2008) . The major toxin found in bee venom is Melittin, a linear 26-residue peptide, which displays strong lytic activity against bacteria and human cells (Habermann 1972) , and it is often used as a positive control in haemolytic assays.
Cell penetrating peptides could have a great pharmaceutical potential as in vitro and in vivo delivery vectors for a wide range of bioactive cargos. CPPs are of different sizes, amino acid sequences, and charges but all published CPPs have the ability to translocate the plasma membrane and facilitate the delivery to the cytoplasm (El-Andaloussi et al. 2005; Hudecz et al. 2005; Morris et al. 2008; Vives et al. 2008) . During the last two decades, several CPPs were described. Tat (transactivator of transcription) and Penetratin, the two most studied CPPs, were derived from the sequence of HIV transactivator protein (Green and Loewenstein 1988) and the third helix of the homeodomain of Drosophila Antennapedia protein (Derossi et al. 1994) . Transportan is a hybrid peptide, constructed from a 6-residue sequence of the neuropeptide Galanin (GWTLNSA-GYLLGPHAVGNHRSFSDKNGLTS) with a peptide toxin from wasp venom (mastoparan, INLKALAALAKKIL) connected via a lysine (Langel et al. 1996) .
Tuftsin is a receptor-binding peptide produced by the enzymatic cleavage of the Fc-domain of the heavy chain of immunoglobulin G. Based on the canine tuftsin sequence, [TKPKG] 4 (OT20) peptide was developed in our laboratory (Bai et al. 2008; Horváti et al. 2012; Mező et al. 2004 ). OT20 peptide, a tetramer derivative of tuftsin, represents comparable chain length (20-m), net charge (9+) and hydrophilicity; therefore, it was used as a negative control in this study.
Materials and methods

Materials
N,N′-Diisopropylcarbodiimide (DIC), triisopropylsilane (TIS) and Amberlit IRA-400 anion-exchange resin were purchased from Fluka. The amino acid derivatives were obtained from Reanal or from IRIS Biotech. 1-Hydroxybenzotriazole (HOBt) and trifluoroacetic acid (TFA) were also from IRIS Biotech. Fmoc-Rink Amide MBHA resin was purchased from NovaBiochem. Acetonitrile and dimethyl sulfoxide (DMSO) were from Merck. N,N-Dimethylformamide (DMF) and dichloromethane (DCM) were from Reanal. Chromatographically purified bovine serum albumin (BSA), 5(6)-carboxyfluorescein (Cf) and 1,8-diazabicyclo[5.4 .0]undec-7-ene (DBU) were obtained from Sigma-Aldrich.
For the in vitro assays RPMI-1640 medium, Dulbecco's Modified Eagle's Medium (DMEM), foetal calf serum (FCS), nonessential amino acids, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), sodium dodecyl sulphate (SDS), BBL TM Löwenstein-Jensen medium slants (ref: 220909) were obtained from BD. Sula medium, PBS buffer (10 mM sodium phosphate in 150 mM NaCl, pH 7.4), Tris buffer (0.1 M tris(hydroxymethyl) aminomethane, pH 7.4, adjusted with HCl), and HPMI buffer (9 mM glucose, 10 mM NaHCO 3 , 119 mM NaCl, 9 mM HEPES, 5 mM KCl, 0.85 mM MgCl 2 , 0.053 mM CaCl 2 , 5 mM Na 2 HPO 4 × 2H 2 O, pH 7.4) were prepared in our laboratory using components obtained from SigmaAldrich. 0.9% NaCl was a Fresenius infusion solution.
Peptide synthesis and purification
Peptides were produced on 100 mg Fmoc-Rink Amide MBHA (capacity = 0.67 mmol/g) resin in an automated peptide synthesizer (Syro-I, Biotage) using standard Fmoc/ t Bu strategy with DIC/HOBt coupling reagents. Peptides were cleaved from the resin with TFA/H 2 O/TIS (9.5: 2.5: 2.5 v/v) mixture (2 h, RT). After filtration, the compounds were precipitated in cold diethyl ether, centrifuged (4000 rpm, 5 min) and freeze dried from water. Crude products were purified by RP-HPLC on a semipreparative C-18 Phenomenex Jupiter column (250 × 10 mm) using gradient elution, consisted of 0.1% TFA in water (eluent A) and 0.1% TFA in acetonitrile/water = 80/20 (v/v) (eluent B).
For the cellular uptake studies, N-terminus of the peptides was labelled with 5(6)-carboxyfluorescein (Cf) using DIC/HOBt coupling method. Cleavage, work-up and purification of Cf-peptides were performed in the same way as mentioned above.
Peptide characterisation
Purified peptides were analysed by RP-HPLC on an analytical C-18 Eurospher-100 (5 µm, 250 × 4 mm) column using gradient elution with the above-mentioned eluent A and B (flow rate was 1 mL/min, UV detection at λ = 220 nm).
Molecular mass of peptides was determined using a Bruker Esquire 3000 + ESI mass spectrometer. Peptide samples were dissolved in a mixture of acetonitrile/ water = 1/1 (v/v) containing 0.1% acetic acid and introduced by a syringe pump with a flow rate of 10 μL/min.
Determination of peptide content by amino acid analysis
The peptide content was determined by amino acid analysis using a Sykam Amino Acid S433H analyser equipped with an ion-exchange separation column and post-column derivatisation. Prior to analysis, samples were hydrolysed with 6 M HCl in sealed and evacuated tubes at 110 °C for 24 h. For post-column derivatisation, the ninhydrin method was used.
Counter-ion replacement and the determination of fluorine content
Acetate exchange of the purified peptides was performed using Amberlit IRA-400 (20-50 mesh, Cl − form) anionexchange resin. First, the resin was washed with water, three times with 0.2 M NaOH, washed with water, and treated with 20% v/v acetic acid. After washing with water, 2 g resin was mixed with the peptide solution (26.5 mg/4 mL of water). The peptide-resin suspension was stirred for 1 h, then filtered and washed with 20% v/v acetic acid and water. After freeze drying, peptides were analysed by analytical RP-HPLC, ESI MS and amino acid analysis. To calculate the anion-exchange rate, the Fluorine content of the peptides was determined using modified Schöniger method (Rogers and Yasuda 1959) . The exchange rate was calculated by dividing the percentage of the Fluorine content of acetate-exchanged peptide by the percentage of the Fluorine content of the original peptide.
Circular dichroism (CD) spectroscopic measurements and secondary structure estimation
Peptide samples were dissolved in deionised water and in 10 mM, pH 7.3 potassium phosphate buffer (0.05 M Na 2 SO 4 ). Far-UV CD curves were acquired on a JASCO J-715 spectropolarimeter at 25 ± 0.2 °C in a 0.1 cm path length rectangular quartz cuvette (Hellma, USA). Temperature control was provided by a Peltier thermostat. The CD data were monitored in continuous scanning mode between 185 and 260 nm at a rate of 50 nm/min, with a step size of 0.1 nm, response time of 2 s, three accumulations, 2 nm bandwidth. The CD curves were corrected by spectral contribution of blank water or buffer solution.CD spectra were plotted in mean residue molar CD units (�ε/residue) calculated by the following equation:
where Θ is the measured ellipticity as a function of wavelength (nm), c is the mean residue molar concentration of the peptide, and l is the optical path length (cm).
The secondary structure content of CM15 was estimated from the CD spectra using the MS Excel version of the
PEPFIT program (Reed and Reed 1997; Amon et al. 2008) . It calculates the percentage of secondary contents by fitting experimental data to reference secondary structure spectra. The best fit is defined by the R 2 value, where an R 2 = 1 corresponds to a perfect fit. Before secondary structure analysis, the CD spectra were smoothed using the Means-Movement method (JASCO Spectra Analysis software, version 1.53.00).
Haemolytic activity assay
Peripheral blood from healthy volunteers was collected in vacuum tubes containing heparin (Li-heparin LH, VenoSafe) as anticoagulant. Tubes were centrifuged (1000 rpm, 5 min) and the pellet was washed three times with RPMI-1640 (culturing media without phenol red). To the pellet, RPMI media were added to yield a final 4, 1, 0.25 or 0.0625% v/v RBC suspension. Peptides were dissolved in the same media and threefold serial dilution series were prepared (final concentration: 0.1-200 μM). RBC suspension (100 μL/well) were placed into a 96-well cell culture plate and mixed with 100 μL peptide solution. The plates were incubated for 4 h at 37 °C. After centrifugation (1500 rpm, 5 min), 100 μL of the supernatant was transferred to a flat bottom microtiter plate and absorbance was measured at 414 nm using an ELISA plate reader (iEMS Reader, Labsystems). The percentage haemolysis was compared to 0.1% Triton-X treated RBC and the concentration of peptide at which 50% haemolysis (HC 50 value) was determined.
To study the time dependence of haemolysis, RBCs were incubated for 30 min or 4 or 24 h with CM15 peptide solution at 37 °C using the same conditions as described above. To compare the effect of different anticoagulants on the haemolysis evoked by CM15 peptide, three types of vacuum tubes were used: heparin (Li-heparin LH, VenoSafe), EDTA (K 3 -EDTA, VenoSafe), citrate (Na 3 -citrate 9NC, VenoSafe). To determine the effect of the addition of stabilizer, BSA was added to the stock solution of the CM15 peptide at 5 mg/mL (0.5%) concentration. The influence of different buffers was tested using either PBS, Tris buffers, Bouillon broth, DMEM, RPMI (without phenol red) media or Fresenius 0.9% NaCl infusion solution. Always the same media were used for washing, culturing the erythrocytes and for dissolving the peptide samples.
Cell culturing, cytotoxicity assay and cell morphology
Peripheral blood mononuclear cells (PBMC) were prepared from peripheral blood of healthy volunteers (purchased from Hungarian National Blood Transfusion Service, HNBTS) using Ficoll-Hypaque density gradient centrifugation method. PBMC were cultured in complete medium prepared from RPMI-1640 supplemented with 10% FCS, 2 mM l-glutamine and 160 µg/mL gentamycin at 37 °C in 5% CO 2 atmosphere. Twenty-four hours prior to treatment, PBMC cells were plated into a 96-well round bottom plate (250,000 cell/100 μL complete medium).
MonoMac6 human monocytic cell line (DSMZ no.: ACC 124) and HepG2 human hepatocellular liver carcinoma cell line (ATCC HB-8065) were maintained under conditions described above. For cytotoxicity assay, cells were distributed on a 96-well flat bottom tissue culture plate (5000 cell/100 μL complete RPMI-1640 medium).
SH-SY5Y human neuroblastoma cell line (ATCC CRL-2266) was cultured in DMEM medium containing 10% FCS, 2 mM l-glutamine, 160 µg/mL gentamycin, 1 mM pyruvate and 1% nonessential amino acids. SH-SY5Y cells (10,000 cell/100 μL complete DMEM medium) were plated into a 96-well flat bottom tissue culture plate.
Prior to treatment, cells were washed with serum-free RPMI-1640 (PBMC, MonoMac6, HepG2) or DMEM (SH-SY5Y) medium. Peptides to be tested were dissolved in serum-free medium and added to the cells to achieve 0.15-300 μM final concentration. Cells were incubated with the peptides for 4 h, then the cell viability was tested using MTT assay (Liu et al. 1997; Mosmann 1983; Slater et al. 1963) . Briefly, 45 μL MTT solutions were added to each well (2 mg/mL, solved in serum-free medium). Following 4 h of incubation, plates were centrifuged at 2000 rpm for 5 min, and the supernatant was carefully aspirated with a G30 needle. The precipitated purple crystals were dissolved in 100 μL DMSO and, after 10 min agitation, the absorbance was determined at λ = 540 nm and 620 nm using ELISA plate reader (iEMS Reader, Labsystems). Cytotoxicity, expressed in percentage as the function of peptide concentration, was represented graphically and IC 50 values were determined.
To visualise cell morphology after peptide treatment, microscopic images of MonoMac6 cells were captured. MonoMac6 cells were plated in a 96-well flat bottom tissue culture plate (5000 cell/100 μL RPMI-1640 medium without phenol red), then treated with the peptides for 4 h at 1, 10 and 100 μM final concentration. Microscopic images of the adherent cells were captured using an Olympus CKX41 microscope.
Cellular uptake studies by flow cytometry
The measurement of cell penetration of the compounds was evaluated on MonoMac6 human monocytic cell line using a BD LSR II flow cytometer (BD Biosciences, San Jose, CA, USA) with 488 nm (Coherent Sapphire, 22 mW) laser. Cells were harvested in the logarithmic phase of growth and plated on a 24-well tissue culture plate (10 5 cells/1 mL medium/well) 24 h prior to the experiment. Cf-labelled peptides were dissolved in serum-free RPMI medium and added to the cells at 20, 10 and 5 µM final concentrations. Cells were incubated with compounds for 2 h (37 °C, 5% CO 2 atmosphere). After centrifugation (1000 rpm, 5 min) and washing with RPMI medium, supernatant was removed and 100 μL 1 mM trypsin was added to the cells. After 5 min incubation at 37 °C, 0.8 mL 10% FCS/HPMI medium was added, then cells were washed and re-suspended in 0.5 mL HPMI. The cell viability was assessed using 10 µg/mL propidium iodide (PI) solution (for the gating strategy, see Supporting Information Figure S1 ). The intracellular fluorescence intensity of the cells was measured on channel PE LP550 (emission at λ = 550 nm) and data were analysed with FACSDiva 5.0 software. All measurements were performed in triplicates. In parallel with flow cytometry measurements, microscopic image of the cells was captured with an Olympus CKX41 microscope.
In vitro antibacterial activity assay
In vitro antibacterial activity of the compounds was determined against Streptococcus pneumoniae (ATCC 49619) by serial dilution method in Bouillon medium, which was prepared in-house. Compounds were added to the medium as 10 μL DMSO solutions in duplicates (range of final concentrations was between 1.2 and 300 μM). Each tube was inoculated with 0.5 Mcfarland bacteria and the minimal Inhibitory concentration (MIC) was determined after incubation at 37 °C for 24 h. MIC was the lowest concentration of a compound at which no visible growth of the bacteria occurred. Antitubercular effect of the compounds was also tested on M. tuberculosis H 37 Rv (ATCC 27294) in Sula semisynthetic medium (prepared in-house) (Sula 1963; Sula and Sundaresan 1963; Vinsova et al. 2006 ) using previously described method (Baranyai et al. 2015; Horváti et al. 2015) . Compounds were dissolved in DMSO and added to the medium at ten various concentrations (c = 0.5-500 μM). MIC value was determined after incubation at 37 °C for 28 days. To confirm the growth inhibition, colony forming unit (CFU) was determined by subculturing from the Sula medium onto drug-free Löwensten-Jensen solid medium. Samples were further incubated for 28 days. Experiments were repeated at least two times.
Selectivity indices were calculated from the concentration value where 50% of human RBCs were lysed (HC 50 ) by the peptides divided by the minimal inhibitory concentration (MIC) determined against S. pneumoniae. Both in vitro measurements were performed in Bouillon broth using 24 h incubation time.
Statistical analysis
In vitro tests were performed in triplicates and the results were expressed as mean ± Std. deviation. For the evaluation of haemolysis and cytotoxicity and for the determination of HC 50 and IC 50 values of the peptides, dose-response curves were plotted with non-linear regression analysis using GraphPad Prism 5.0 software. The effects of different experimental conditions (incubation time, media, percentage of RBC, anticoagulant and counter-ion) were analysed by one-way ANOVA test using GraphPad Prism 5.0 software. If means were significantly different (P < 0.05), then ANOVA test was followed by a t test (unpaired, two-tailed, confidence intervals: 95%).
Results and discussion
Representative examples of cationic oligopeptides, listed in Table 1 , were critically analysed and compared in well-defined in vitro assays. Our aim was to find good future peptide candidates for antimicrobial drug delivery. Cytotoxicity, haemolytic and antimicrobial activity of membrane-active peptides are often used to estimate their therapeutic applicability (Helmerhorst et al. 1999; Maher and McClean 2006) . In this paper, we show that the calculated selectivity index is strongly dependent on the conditions (i.e. culturing media) of the in vitro assays. Therefore, systematic studies were performed to establish proper test conditions for accurate comparison. All 11 peptides were then tested on PBMC and MonoMac6 cells, against two bacterial strains (S. pneumoniae and M. tuberculosis) and on human erythrocytes in different incubation media. As positive control, Melittin was used which has strong lytic activity against microbes and human cells. OT20 was the negative control in this study. OT20 is a non-membraneactive, receptor binding peptide, which represents comparable cationic character.
Synthesis and characteristics of cationic peptides
Cationic peptides, listed in Table 2 , were synthesised, purified and carefully characterised by analytical RP-HPLC, ESI MS and amino acid analysis.
In the course of the experimental design, it is important to note that the peptide content of a lyophilised material can vary according to the sequence and the used synthetic procedures. Generally, the content of residual salt and water, which are the main impurities in a lyophilised peptide, can be up to 40-50%, especially in the case of high number of positively charged amino acids in the sequence. For more reliable comparison, precise determination of peptide content was evaluated by amino acid analysis. We found that the higher the average hydrophilicity (H), the lower the peptide content was measured. The average peptide content was 50%, the lowest value was 41% for Tat (47-57) peptide (9+ charge in 11 amino acids), and the highest was 58% for Magainin (4+ charge in 23 amino acids) ( Table 2) .
Counter-ion replacement
After standard solid phase synthesis and purification, cationic peptides are often isolated as trifluoroacetate salts (Roux et al. 2008; Vemuri 2005 ). In the case of lysine and arginine rich peptides, the high amount of TFA can modify the biological and physicochemical properties (i.e. by affecting the conformation of the peptide, acidifying the media, and lowering the peptide content of the lyophilised (Bai et al. 2008) powder). Therefore, we have changed the trifluoroacetate counter-ion for acetate (which is less acidic, toxic and has lower molecular mass) using Amberlit IRA-400 anionexchange resin. This process also removed the excess TFA. Anion-exchange rate was monitored by elemental analysis. The fluorine content of the peptide after acetate exchange was decreased dramatically and the calculated exchange rate was up to 80% [F% = 13.42 (unchanged peptide); 2.88 (acetate-exchanged)].
Circular dichroism spectroscopic investigation of the secondary structure of CM15 peptide
Far-UV CD spectra of peptides represent the summation of signals from the optically active n-π* and π-π* transitions of the amide bonds (Toniolo et al. 2012 ). α-Helical structures display a negative n-π* CD band at ~220 nm and two higher intensity negative-positive peaks at ~207 and ~190 nm, respectively. This couplet is attributable to chiral exciton interaction of the helically arranged amide chromophores. The β-sheet CD pattern consists of a negative n-π* band near 217 nm and two π-π* exciton components below 200 nm. Unordered peptides and proteins show a strong negative peak centered in the 195-200 nm region and a substantially weaker, positive or negative signal above 215 nm. Taking these into consideration, the CD curve of CM15 measured in water (pH ~6) reflects the dominant contribution of the unordered or random coil structure ( Fig. 1) (Pistolesi et al. 2007 ).
In full concordance with this, quantitative analysis of the CD data yielded 62% random coil and 26% β-sheet with no α-helical content. Interestingly, a small fraction of type III β-turn (Reed and Reed 1997) was also required to achieve the best fit between the experimental and calculated data (Fig. 1) . In relation to water, the negative CD band is red shifted above 200 nm in buffer solution together with the development of a prominent shoulder above 215 nm. According to the secondary structure estimation, these spectral changes can be associated with a β-turn → α-helix conformational conversion (Fig. 1) . These results suggest that the pH of the medium where CM15 acts, e.g. normal or acidic inflamed tissues, may provoke a slight, but significant modification in its secondary structure.
Haemolytic activity of peptides: effect of experimental conditions
Published methods to determine haemolytic activity of cationic peptides often use different test conditions that can strongly influence the results. Therefore, the effect of time, incubation buffer, concentration of RBC, identity of anticoagulant and counter-ion on haemolytic activity of cationic peptides were investigated. To establish proper test conditions, CM15 peptide was chosen because of its average characteristics (charge and size) and medium haemolytic activity. 
Incubation time and media
First, the time dependence of haemolysis evoked by cationic peptides was studied. Erythrocytes were incubated for 30 min, 2, 4 or 24 h with CM15 peptide. Half an hour was enough to reach the maximum haemolysis; no further haemoglobin release was detected (Fig. 2a, b) . On comparing the means of the HC 50 values, no significant difference was observed (P = 0.4449). In contrast, the type of incubation media strongly influenced the haemolytic activity of CM15 peptide. The resulted means of HC 50 values showed significantly difference (P < 0.0001) in the one-way ANOVA test. In the measurement of haemolysis, isotonic conditions are required to prevent erythrocytes from spontaneous lysis. Most commonly, PBS and Tris buffers are used in haemolytic assays; however, for antimicrobial and cytotoxic assays these are considered to be high salt buffers (Helmerhorst et al. 1999) . RPMI, DMEM and other cell culturing media contain amino acids, vitamins, glucose as well as additional supplementary components to be optimal for cultivation of certain cell types and are formulated to have the final osmolality in the range of 290-310 mOs/kg. It was found that the haemolytic activity of CM15 peptide is significantly lower (P < 0.0001) in PBS (28.2 ± 1.22 μM) than in cell culturing DMEM media (DMEM: 6.70 ± 0.50 μM). Haemolysis in RPMI, DMEM and Bouillon broth was in the range of 6.70-15.32 μM (Fig. 2c, d ). For other cationic peptides, same results were found, namely lower HC 50 values were measured in PBS and Tris buffers than in cell culturing media and broths (data not shown).
In published methods, there are differences even in the used wavelength at which the absorbance of the supernatant is measured. Percentage of haemolysis is calculated by dividing the absorbance measured for the peptide by the absorbance measured for the positive control (both values are corrected with the background). Therefore, the resulted % haemolysis values are independent of the exact absorbance values. However, better results can be obtained if we measure at the wavelength maximum of the Fig. 1 Far-UV CD spectra of CM15 peptide. CM15 (30 μM) was measured in deionised water (pH ~6, 0.05 M Na 2 SO4) and in 10 mM, pH 7.3 potassium phosphate buffer (0.05 M Na 2 SO4), (a). b The results of the curve-fitting procedure made using the PEPFIT analysis program (α-H α-helix, β-S β-sheet, r-C random coil; β-T type III β-turn). The inset shows the estimated secondary structure percentages of the peptide Fig. 2 Effect of incubation time (a, b) and media (c, d) on the haemolytic activity of CM15 peptide. Human erythrocytes were treated with CM15 peptide at various concentrations using different experimental conditions and the haemolysis was determined by reading the absorbance of the supernatant at λ = 414 nm. Haemolysis of the erythrocytes reached the maximum after 30 min treatment and no further haemoglobin release was measured. The haemolytic activity of CM15 peptide is strongly dependent on the used incubation buffer: in PBS significantly lower HC 50 value was measured than in low ionic strength media or broth. (One-way ANOVA test, means are significantly different, P < 0.0001) released haemoglobin. We found that the highest values can be measured if we monitor the absorbance at 414 nm or 405 nm (Table 3) .
Concentration of red blood cells, presence of BSA, anticoagulant and counter-ion
The percentage or cell number of RBC used in haemolytic assays differs in a wide concentration range. Therefore, to clarify the effect of RBC content, haemolysis of CM15 peptide was studied at 4, 1, 0.25 or 0.0625% RBC concentration. No difference was measured (P = 0.2862) for 4, 1, 0.25%, while at 0.0625% RBC concentration significantly lower HC 50 value was measured (P = 0.0004) (Fig. 3a) Peptide and protein solutions are prone to loose activity as a result of aggregation, loss of original structure integrity and/or binding to the storage vessel. Therefore, it is widely recommended to dilute the samples in a buffer containing a stabilizer. The addition of bovine serum albumin (BSA) in a concentration of 1-10 mg/mL (0.1-1%) is a popular way to protect against such degradation and loss. To study the effect of BSA addition, CM15 peptide was diluted in the presence of 5 mg/mL (0.5%) BSA and the haemolytic activity was tested. The results showed that the addition of BSA has no significant effect on the haemolytic activity of CM15 peptide (P = 0.1018) (Fig. 3b) .
Although published methods for analysis of haemolytic activity of cationic peptides mentioned different anticoagulant containing vacuum tubes for cupping, no systematic study was evaluated on the effect of anticoagulants. Therefore, most frequently used anticoagulant containing vacuum tubes were used to compare the effect of citrate, heparin and EDTA on the haemolytic activity of CM15 peptide. The results clearly showed that lysis of the red blood cells by CM15 was independent of the used anticoagulant (P = 0.1210) (Fig. 3c ).
In the case of lysine and arginine rich peptides, the high amount of TFA could alter the biological activity. Therefore, excess TFA and trifluoroacetate counter-ion was removed and changed to acetate counter-ion and the haemolytic activity of trifluoroacetate and acetate counterion containing CM15 peptide was assayed. No marked effect of counter-ion identity could be observed in case of CM15 peptide treated RBC (P = 0.4106) (Fig. 3d) .
Cytotoxicity of cationic peptides
Cytotoxicity of cationic peptides was studied on freshly prepared human PBMC in RPMI media (incubation time was 4 h) using MTT test. PBMC are isolated human cells which can be used to study general toxicity of a compound. The following order of cytotoxicity was found: (1) Melittin, Transportan, CM15 and Dhvar4 peptides have IC 50 value lower than 50 μM; (2) modest cytotoxicity (50-300 μM) was measured for GranF2, Magainin and Penetratin; (3) Tat(47-57), Buforin II, Crot(1-9,38-42) and OT20 peptides were not cytotoxic up to 300 μM (Table 4) .
When measuring the haemolytic activity of the peptides employing the same experimental conditions as for the . No significant differences in the resulted HC 50 values were detected after using three different anticoagulants (c). Counter-ion replacement has no significant effect on the haemolytic activity of CM15 peptide cytotoxic assay (RPMI media, 4 h of incubation), almost the same order of activity was found, namely the highest HC 50 values were measured for Melittin, Transportan, CM15, and Transportan. Dhvar4 and GranF2 peptides were found to be cytotoxic to PBMC cells but not for red blood cells (HC 50 > 300 μM).
To estimate the cell type dependence of cationic peptides, four different human cells and cell lines were used. HepG2 human hepatocytes and SH-SY5Y human neuroblastoma cells are frequently used as hepatotoxicity and neurotoxicity model. MonoMac6 human monocytic cell line is a macrophage model which is suitable to bear intracellular bacteria. Cells were treated with Transportan at various peptide concentrations and the cytotoxicity was determined by MTT assay. Mean IC 50 values showed significant difference (P < 0.05); however, all IC 50 values were in the same concentration range: 4.70 ± 1.02 μM (MonoMac6), 6.78 ± 0.488 μM (HepG2), 8.28 ± 0.573 μM (SH-SY5Y), 9.81 ± 0.473 μM (PBMC) (Fig. 4) .
MonoMac6, which are adherent cells, were chosen to visualise the changes in the cell morphology caused by cationic peptides (Fig. 5) . Microscopic images of the peptide-treated cells were captured using an Olympus CKX41 microscope. After treatment with Buforin II (5-21), Crot(1-9,38-42) and OT20 peptides, intact MonoMac6 cells were observed. Melittin, Transportan, CM15, Dhvar4 and GranF2 peptides caused severe damage on the cell membrane and provoked dramatic changes in the cell morphology. Penetratin, Magainin and Tat(47-57) peptides affected the cell membrane integrity just at the highest (100 μM) concentration. These microscopic observations are in accordance with the result of the MTT assay.
Internalisation of cationic peptides
Cellular uptake of MonoMac6 human monocytic cells was measured by flow cytometry. For that purpose, peptides were labelled with 5(6)-carboxyfluorescein (Cf) and measured at 20, 10 and 5 µM final concentrations (Fig. 6) . Based on the internalisation ability, three groups of peptides were created: (1) superior penetration was defined for peptides where the percentage of FITCpositive cells was higher than 80% at 5 µM concentration-Penetratin, Transportan, Dhvar4 and Melittin; (2) good penetration for peptides where the percentage of FITC-positive cells was higher than 50% at 10 µM concentration-Tat, GranF2, CM15 and Buforin II; and (3) modest penetration where the percentage of FITC-positive cells was higher than 50% at 20 µM concentrationCrot(1-9,38-42), Magainin II and OT20. It is important to note that peptides with superior penetration show the highest cytotoxicity, especially Melittin, Transportan and Dhvar4. However, Penetratin, Tat and Buforin II peptides bear good internalisation property but low cytotoxicity.
Antibacterial activity against S. pneumonia
Antimicrobial efficacy of cationic peptides was measured against S. pneumoniae, a Gram-positive bacterium which is one of the most significant human pathogens (Table 4) . Buforin II, Crot(1-9,38-42), Tat and OT20 control peptide were not effective against S. pneumonia. Magainin and GranF2 showed modest activity; CM15 and Dhvar4 peptides had potent antibacterial activity (less than 4 μM) just as Melittin. Interestingly, Penetratin and Transportan, which are classified as cell penetrating peptides, showed relevant antibacterial activity against S. pneumoniae. In the case of Penetratin, these findings are in accordance with a previous data, which suggested that the membrane induced α-helical structure makes this peptide similar in activity to AMPs (Magzoub et al. 2002; Zhu and Shin 2009) . 
Transportan is effective against M. tuberculosis
Antitubercular effect of all peptides was tested also on M. tuberculosis H 37 Rv strain. M. tuberculosis, the causative agent of tuberculosis, can survive in the host phagocytes for years or even decades and it is estimated that more than one-third of the world's population are infected with these pathogens (Lienhardt et al. 2012) . Our results demonstrated that none of the peptides were effective against M. tuberculosis up to 300 μM concentration, except Transportan. The MIC of Transportan peptide was 80 μM. No published data were found recently on the antitubercular effect of Transportan.
In vitro selectivity of cationic peptides
We found that the haemolytic activity of the tested peptides is significantly lower in PBS than in RPMI or in Bouillon broth. Therefore, selectivity indices (given in Table 4 ) were calculated from the results of experiments using the same buffer and incubation time. Based on the comparison of antitubercular effect and haemolytic activity, most selective peptides (where the selectivity indices were higher than 20) were Penetratin, Dhvar4 and Transportan. Among these peptides, Penetratin showed the best selectivity, because the MIC value of Penetratin was 250 times lower than its HC 50 value. Modest selectivity was found for Magainin II, GranF2 and CM15 peptides. Up to the highest concentration (300 μM) no antibacterial and haemolytic activities were observed for Buforin II, Crot(1-9,38-42), Tat and OT20 peptides (Table 4 ). In the case of the positive control peptide Melittin, the MIC value was higher than the HC 50 value.
Conclusion
Here, we report the comparative analysis of cationic oligopeptides to identify potent antibacterial carriers for drug delivery. Peptide synthesis and purification were followed by accurate characterisation of the product (molecular mass, retention time, peptide content). Haemolytic activity and cytotoxicity of the peptides on isolated human blood cells and different cell lines have been systematically studied and compared to their penetrating ability and antibacterial activity against S. pneumoniae (pneumococcus) and M. tuberculosis. We also clarified the role of the used media, incubation time, RBC concentration, addition of BSA, type of anticoagulant and counter-ion on the haemolytic activity of the peptides. We found that the lytic activity strongly depends on the incubation media, which observation is in accordance with the results of the CD spectroscopic measurements. Therefore, it is uncertain whether the results of haemolytic assays, that are conducted in high salt buffers such as Tris or PBS, can be compared properly with the results of antibacterial assays that are conducted in low ionic strength buffers or broths. Because of this observation, the same incubation media were applied both for the antibacterial and the haemolytic assay. We also found that the haemolytic activity of cationic peptides was almost independent from the other conditions like incubation time and type of anticoagulant. For a proper haemolytic assay, performed on human erythrocytes, at least 0.25% v/v RBC concentration is required, which is equal to approximately 1-1.25 × 10 7 cells/mL (counting with the reference range of RBC of a male or female blood). When measuring the cytotoxicity of cationic peptides on different human cells and cell lines, almost the same order of activity was found than in the haemolytic assay. As a summary of the performed assays we can conclude the following: (1) eight peptides showed superior or good penetration of which Tat, Penetratin, Dhvar4 and Buforin has low haemolytic activity. Therefore, these peptides can be considered as good carriers for different drug molecules without causing severe damage on human cells. (2) Transportan was found to be effective against M. tuberculosis H 37 Rv bacteria. However, Transportan was cytotoxic at this concentration range. (3) Dhvar4 peptide showed superior antibacterial effect and penetration ability although this peptide was cytotoxic to human PBMC but not to human erythrocytes. (4) Penetratin was identified as promising antibacterial drug carrier with potent antibacterial effect (MIC lower than 1.2 μM on pneumococcus) and superior penetration ability with low in vitro toxicity on human cells. Conjugation of an antibacterial drug to an antibacterial peptide is proposed to intensify the efficacy by multiple mode of action: including bacterial cell lysis, inhibiting bacterial enzymes, interacting directly with the cytoplasmic membrane and inhibiting intracellular targets. In addition, the consequence of the multiple mechanism of action is the low potential to induce microbial resistance. Therefore, Penetratin and its analogues with remarkable antibacterial activity and high selectivity will be further investigated as drug delivery systems for antibacterial agents.
